Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
48 |
Employees |
25 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-52 |
Cash Flow (TTM) (Millions $) |
-11 |
Capital Exp. (TTM) (Millions $) |
0 |
Entasis Therapeutics Holdings Inc
Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company that is focused on developing novel, breakthrough treatments for serious bacterial infections. The company's mission is to address the urgent need for new drugs to treat drug-resistant infections, which are responsible for thousands of deaths each year.
Founded in 2015 in Waltham, Massachusetts, Entasis Therapeutics Holdings Inc has since become recognized as a leader in the field of anti-infectives. The company's team of experts have a deep understanding of bacterial pathogens, and use that knowledge to design and develop innovative therapies that target the underlying mechanism of antibiotic resistance.
Entasis Therapeutics Holdings Inc is dedicated to developing novel treatments for serious bacterial infections that have been designated by the World Health Organization as priority pathogens. These include multidrug-resistant Gram-negative bacteria such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae (including Klebsiella pneumoniae and Escherichia coli) as well as infections caused by the Gram-positive Staphylococcus aureus.
The company's pipeline includes multiple potential new therapies in various stages of development. Its lead product candidate, zoliflodacin, is a first-in-class oral antibiotic that targets the bacterial enzyme DNA gyrase, promising a new option for the treatment of uncomplicated gonorrhea. Zoliflodacin received the prestigious Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA).
Another product candidate in pre-clinical development, ETX0282CPDP, is a potent inhibitor of the bacterial enzyme LpxC, which plays a critical role in the biosynthesis of the bacterial cell wall. ETX0282CPDP demonstrates activity against a wide range of Gram-negative bacteria, including those resistant to multiple antibiotics.
Entasis Therapeutics Holdings Inc works collaboratively with various organizations, including academic institutions, government agencies, and pharmaceutical companies to accelerate the development of its pipeline products. The company is committed to addressing the global public health crisis of antibiotic resistance, by creating new, effective therapies that can help patients fight serious infections, while also preserving the efficacy of existing therapies over time.
Company Address: 35 Gatehouse Drive Waltham 2451 MA
Company Phone Number: 810-0120 Stock Exchange / Ticker: NASDAQ ETTX
|